Literature DB >> 32694753

D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice.

Dong-Liang Tang1, Yi-Wen Luan1, Chun-Yi Zhou2,3, Cheng Xiao4,5.   

Abstract

Chronic pain is a common and undertreated nonmotor symptom in Parkinson's disease (PD). Although chronic pain is improved by L-dopa in some PD patients, the underlying mechanisms remain unclear. In this study, we established PD mice by unilateral microinjection of 6-OHDA in the medial forebrain bundle to investigate the contribution of spinal cord dopamine receptors to parkinsonian pain hypersensitivity. The von Frey filament tests and thermal pain tests revealed that these PD mice displayed decreased nociceptive thresholds in both hindpaws; intrathecal injection of L-dopa or apomorphine significantly increased the mechanical and thermal nociceptive thresholds, and the analgesic effect was mimicked by ropinirole (a D2 receptor agonist), but not SKF38393 (a D1/D5 receptor agonist), and blocked by sulpiride (a D2 receptor antagonist), but not SKF83566 (a D1/D5 receptor antagonist). Whole-cell recordings in lumber spinal cord slices showed that superficial dorsal horn (SDH) neurons in PD mice exhibited hyperexcitability, including more depolarized resting membrane potentials and more action potentials evoked by depolarizing current steps, which were mitigated by ropinirole. Furthermore, ropinirole inhibited the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) in SDH neurons more strongly in PD mice than in control mice. However, sulpiride caused less disinhibition of sEPSCs in PD mice than in control mice. Taken together, our data reveal that pain hypersensitivity in PD mice is associated with hyperexcitability of SDH neurons, and both events are reversed by activation of spinal D2 receptors. Therefore, spinal D2 receptors can be promising therapeutic targets for the treatment of PD pain.

Entities:  

Keywords:  Parkinson’s disease; dopamine D2 receptor; dorsal horn neuron; hyperexcitability; intrathecal administration; pain hypersensitivity; spinal cord; whole-cell recording

Mesh:

Substances:

Year:  2020        PMID: 32694753      PMCID: PMC8027812          DOI: 10.1038/s41401-020-0433-3

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  47 in total

Review 1.  Pain in Parkinson's disease.

Authors:  Ainhi D Ha; Joseph Jankovic
Journal:  Mov Disord       Date:  2011-09-23       Impact factor: 10.338

2.  [Pain in Parkinson's disease: prevalence, characteristics, associated factors, and relation with other non motor symptoms, quality of life, autonomy, and caregiver burden].

Authors:  Diego Santos-García; Javier Abella-Corral; Ángel Aneiros-Díaz; Helena Santos-Canelles; Miguel A Llaneza-González; Mercedes Macías-Arribi
Journal:  Rev Neurol       Date:  2011-04-01       Impact factor: 0.870

Review 3.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Authors:  K Ray Chaudhuri; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

4.  Parkinson's disease and pain: Modulation of nociceptive circuitry in a rat model of nigrostriatal lesion.

Authors:  Roberta A Domenici; Ana Carolina P Campos; Soraya T Maciel; Miriã B Berzuino; Marina S Hernandes; Erich T Fonoff; Rosana L Pagano
Journal:  Exp Neurol       Date:  2019-02-14       Impact factor: 5.330

Review 5.  Pains in Parkinson disease--many syndromes under one umbrella.

Authors:  Gunnar Wasner; Günther Deuschl
Journal:  Nat Rev Neurol       Date:  2012-04-17       Impact factor: 42.937

Review 6.  Pain in Parkinson's disease: new concepts in pathogenesis and treatment.

Authors:  Katarina Rukavina; Valentina Leta; Carolina Sportelli; Yazead Buhidma; Susan Duty; Marzia Malcangio; Kallol Ray Chaudhuri
Journal:  Curr Opin Neurol       Date:  2019-08       Impact factor: 5.710

7.  Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.

Authors:  Christine Brefel-Courbon; Pierre Payoux; Claire Thalamas; Fabienne Ory; Isabelle Quelven; François Chollet; Jean Louis Montastruc; Olivier Rascol
Journal:  Mov Disord       Date:  2005-12       Impact factor: 10.338

8.  Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study.

Authors:  A Gerdelat-Mas; M Simonetta-Moreau; C Thalamas; F Ory-Magne; T Slaoui; O Rascol; C Brefel-Courbon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-15       Impact factor: 10.154

9.  Neurophysiologic study of central pain in patients with Parkinson disease.

Authors:  P Schestatsky; H Kumru; J Valls-Solé; F Valldeoriola; M J Marti; E Tolosa; M L Chaves
Journal:  Neurology       Date:  2007-12-04       Impact factor: 9.910

10.  Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Jihye Park; Chae-Seok Lim; Hyunhyo Seo; Chung-Ah Park; Min Zhuo; Bong-Kiun Kaang; Kyungmin Lee
Journal:  Mol Pain       Date:  2015-05-17       Impact factor: 3.395

View more
  2 in total

1.  Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice.

Authors:  Kinga Sałat; Anna Furgała-Wojas
Journal:  Molecules       Date:  2021-04-20       Impact factor: 4.411

2.  Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine.

Authors:  Wei Zhang; Ming Lei; Qianwen Wen; Dunke Zhang; Guangcheng Qin; Jiying Zhou; Lixue Chen
Journal:  J Headache Pain       Date:  2022-08-10       Impact factor: 8.588

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.